Personalis announced the launch of its universal cancer immunogenomics platform, ImmunoID NeXT. This is the first platform to enable comprehensive analysis of both a tumor and its microenvironment from a single sample.
“While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor immunogenomics,” Personalis CEO, John West, said. “With ImmunoID NeXT, it’s now possible to characterize the complex interactions between the tumor cells and immune cells of the microenvironment using a single platform. This means researchers no longer have to make the difficult choice of which biomarkers to analyze due to sample limitations, particularly when dealing with FFPE specimens.”
The unique design of the ImmunoID NeXT Platform facilitates the delivery of therapeutic and diagnostic biomarker information across 20,000 genes from DNA and RNA, including:
- Neoantigen identification and characterization
- Human leukocyte antigens (HLA) typing
- Tumor infiltrating adaptive immune cells
- T-cell receptor (TCR) repertoire (α, β, γ, and δ chains)
- B-cell receptor (BCR) repertoire (heavy and light chains)
- Tumor infiltrating innate immune cells
- Immune response and tumor escape mechanisms
- Neoantigen load and tumor mutational burden (TMB)
- Microsatellite instability (MSI) status
- Oncoviral detection
- Germline genomic variation